TriNetX will link its large de-identified health database with Regeneron for genomic and proteomic data access under an exclusive, secure, licensed arrangement covering roughly 300 million individuals. The effort is designed to expand Regeneron’s discovery and development capabilities by combining real-world health data with higher-dimensional biological measurements. For biotech programs, the deal signals ongoing push toward hybrid analytics—using network-scale clinical records to inform translational hypotheses and to accelerate target identification and patient stratification. Proteomic and genomic enrichment can help refine biomarker discovery, safety signals, and subgroup analyses. The practical impact will depend on how quickly Regeneron can translate linked multi-omics into actionable endpoints for trials, including inclusion/exclusion strategies and pharmacodynamic markers.